

# A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

NCT07294365

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Dizal Pharmaceuticals
Enrollment	60 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Male and female participants  $\geq 18$  years of age.
- Diagnosed with persistent or chronic primary ITP, and an average of two platelet counts  $< 30 \times 10^9/L$ .
- Have failed at least one standard treatment for ITP (glucocorticoids and/or IVIG).
- Adequate bone marrow reserve and organ functions.
- Willing to comply with contraceptive restrictions.

### Exclusion (8)

- Have evidence of secondary causes of immune thrombocytopenia.
- Have a history of coagulation disorders other than ITP, such as disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura.
- Any of previous or current treatment prohibited by protocol.
- Any of severe cardiac abnormalities.
- Active infection.

... and 3 more (see full listing online)

## Locations (1 total)

---

Qilu Hospital of Shandong University, Jinan, Shandong, China